ASCENT: Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Primary endpoint (PFS by blinded independent central review, patients without brain metastases): 5.6 vs 1.7 months — HR 0.41 (95% CI 0.32–0.52; P<0.001) Key secondary (OS, patients without brain metastases): 12.1 vs 6.7 months — HR 0.48 (95% CI 0.38–0.59; P<0.001) Safety signal: Neutropenia (grade 3: 34%, grade 4: 17%) and diarrhea (grade 3: 10%) with sacituzumab govitecan

📱 Clinic quick reference: Mobile version — save for point-of-care use

Clinical Bottom Line

Sacituzumab govitecan demonstrated a clinically meaningful and statistically significant improvement in both progression-free survival and overall survival compared with physician's choice single-agent chemotherapy in patients with metastatic triple-negative breast cancer who had received at least two prior lines of treatment. The trial was stopped early by the data and safety monitoring committee because of compelling evidence of efficacy. The survival advantage was observed consistently across all prespecified subgroups, including patients previously treated with checkpoint inhibitors and those with liver metastases.

This trial established sacituzumab govitecan as a standard-of-care option in the third-line and beyond setting for metastatic triple-negative breast cancer. Before ASCENT, there was no regimen in this space that had demonstrated an overall survival benefit over standard single-agent chemotherapy. As of 2026, sacituzumab govitecan occupies a central role in the later-line treatment algorithm for metastatic TNBC, and subsequent trials have explored its use in earlier lines and in combination with other agents.

The dominant toxicity concern is myelosuppression — particularly neutropenia — which required growth-factor support in nearly half of patients. Diarrhea was also significantly more frequent with sacituzumab govitecan. However, rates of treatment discontinuation due to adverse events were low and identical between arms, and no treatment-related deaths occurred in the sacituzumab govitecan group. The safety profile is manageable with proactive supportive care but demands vigilant monitoring.

Trial Overview

Study Design

• Trial name and registration: ASCENT (NCT02574455; EudraCT 2017-003019-21)
• Design: Phase 3, randomized, open-label with blinded independent central review for the primary endpoint, final analysis
• Randomization: 1:1 ratio, stratified by number of previous chemotherapy regimens for advanced disease (2 or 3 vs. >3), presence of known brain metastases at baseline (yes vs. no), and geographic region (North America vs. rest of the world)
• Setting: Metastatic triple-negative breast cancer, relapsed or refractory, ≥2 prior lines of chemotherapy
• Enrollment period and sites: November 2017 to September 2019 at 88 sites in seven countries. The trial was halted in March 2020 on unanimous recommendation of the data and safety monitoring committee owing to compelling evidence of efficacy.

Mechanism of Action

Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate composed of a humanized anti-Trop-2 monoclonal antibody linked to SN-38, the active metabolite of irinotecan, via a proprietary hydrolyzable linker. Trop-2 is a cell-surface antigen highly expressed in many epithelial cancers, including triple-negative breast cancer. The antibody binds to Trop-2-expressing tumor cells, and the conjugate is internalized, releasing SN-38 intracellularly to induce topoisomerase I–mediated DNA damage and cell death. The hydrolyzable linker also allows bystander killing of adjacent tumor cells [2].

Patient Population

• Key eligibility: Patients with metastatic triple-negative breast cancer that was relapsed or refractory to two or more previous standard chemotherapy regimens for unresectable, locally advanced or metastatic disease. Previous therapy had to include a taxane. There was no upper limit on the number of prior regimens. Patients with stable brain metastases for at least 4 weeks before treatment were eligible for the trial but were excluded from the primary endpoint analysis.
• Biomarker selection: Triple-negative breast cancer according to standard American Society of Clinical Oncology–College of American Pathologists criteria (lack of ER, PR, HER2 expression)
• Sample size flow: Screened: not reported in this publication → 529 randomized (267 sacituzumab govitecan, 262 chemotherapy) → 482 treated (258 sacituzumab govitecan, 224 chemotherapy) → 468 analyzed for the primary efficacy population (patients without brain metastases: 235 sacituzumab govitecan, 233 chemotherapy). The 32-patient difference between randomized and treated in the chemotherapy arm was accounted for by 26 patients who received no trial drug and 6 who withdrew consent before treatment; these 32 patients were included in efficacy but excluded from safety analyses.

Baseline Characteristics

Baseline characteristics are presented for the primary efficacy population (patients without brain metastases).

Baseline characteristics were well balanced between the two arms. All patients had received prior taxanes. Prior anthracycline use was reported in 191 (81%) and 193 (83%) of the sacituzumab govitecan and chemotherapy groups, respectively. Prior carboplatin use was reported in 147 (63%) and 160 (69%), and prior capecitabine in 147 (63%) and 159 (68%).

Treatment Protocol

Experimental Arm: Sacituzumab Govitecan (n=267 randomized full population; n=235 primary efficacy population; safety population n=258)

Sacituzumab govitecan (Trodelvy) 10 mg per kilogram of body weight intravenously on days 1 and 8 of each 21-day cycle.

• Dose and schedule: 10 mg/kg IV on days 1 and 8 of each 21-day cycle
• Treatment duration: Until disease progression, unacceptable toxic effects, withdrawal from the trial, or death

• Median treatment duration: 4.4 months

• Median relative dose intensity: 99.7%

Control Arm: Chemotherapy (n=262 randomized full population; n=233 primary efficacy population; safety population n=224)

Single-agent chemotherapy of physician's choice, prespecified before randomization: eribulin (54%), vinorelbine (20%), capecitabine (13%), or gemcitabine (12%).

• Dose and schedule: Eribulin (1.4 mg/m² [North America] or 1.23 mg/m² [Europe] IV on days 1 and 8 of 21-day cycle), vinorelbine (25 mg/m² IV on day 1 weekly), capecitabine (1000 to 1250 mg/m² orally twice daily on days 1 to 14 of 21-day cycle), or gemcitabine (800 to 1200 mg/m² IV on days 1, 8, and 15 of 28-day cycle)
• Treatment duration: Until disease progression, unacceptable toxic effects, withdrawal from the trial, or death
• Median treatment duration: Not reported in this publication

No crossover to sacituzumab govitecan was allowed on progression with chemotherapy.

Efficacy Outcomes

Primary Endpoint: Progression-Free Survival (Blinded Independent Central Review) Among Patients Without Brain Metastases

Definition: Time from randomization until objective tumor progression or death, as determined by blinded independent central review according to RECIST version 1.1, among patients without known baseline brain metastases

Analysis population: Patients without brain metastases at baseline (N=468)

Statistical method: Kaplan–Meier method; stratified log-rank test; stratified Cox proportional-hazards model

Median follow-up: 17.7 months (range, 5.8 to 28.1)

Sacituzumab Govitecan: 5.6 months (95% CI, 4.3 to 6.3); 166 events in 235 patients Chemotherapy: 1.7 months (95% CI, 1.5 to 2.6); 150 events in 233 patients Comparison: HR 0.41 (95% CI, 0.32 to 0.52; P<0.001)

A hierarchical testing procedure (gatekeeping) was implemented for testing PFS and OS to control the type I error rate at a two-sided alpha level of 0.05. The primary endpoint boundary was crossed. The planned design specified 315 PFS events for 95% power; 316 total PFS events (166 + 150) occurred in the primary population.

Key Secondary Endpoints

Overall Survival Among Patients Without Brain Metastases

This endpoint was formally tested within the statistical hierarchy.

Analysis population: Patients without brain metastases at baseline (N=468)

Sacituzumab Govitecan: 12.1 months (95% CI, 10.7 to 14.0); 155 events Chemotherapy: 6.7 months (95% CI, 5.8 to 7.7); 185 events Comparison: HR 0.48 (95% CI, 0.38 to 0.59; P<0.001)

Progression-Free Survival (Investigator Assessment) Among Patients Without Brain Metastases

Sacituzumab Govitecan: 5.5 months Chemotherapy: 1.7 months Comparison: HR 0.35 (95% CI, 0.28 to 0.44)

Investigator assessment was consistent with central review results.

Objective Response Among Patients Without Brain Metastases

Analysis population: Patients without brain metastases at baseline (N=468)

Sacituzumab Govitecan: 35% (82 of 235 patients; including 10 [4%] complete responses and 72 [31%] partial responses) Chemotherapy: 5% (11 of 233 patients; including 2 [1%] complete responses and 9 [4%] partial responses)

Clinical benefit rate (objective response or stable disease ≥6 months) was 105 (45%) with sacituzumab govitecan versus 20 (9%) with chemotherapy.

Duration of Response Among Patients Without Brain Metastases

Analysis population: Responders in primary efficacy population

Sacituzumab Govitecan: 6.3 months (95% CI, 5.5 to 9.0) Chemotherapy: 3.6 months (95% CI, 2.8 to could not be estimated) Comparison: HR 0.39 (95% CI, 0.14 to 1.07)

Efficacy in the Full Population (Including Patients with Brain Metastases)

Results in the full population (N=529, including 61 patients with brain metastases) were consistent with the primary efficacy population:

PFS (BICR):

• Sacituzumab Govitecan: 4.8 months (95% CI, 4.1 to 5.8); 190 events
• Chemotherapy: 1.7 months (95% CI, 1.5 to 2.5); 171 events
• HR 0.43 (95% CI, 0.35 to 0.54)

OS:

• Sacituzumab Govitecan: 11.8 months (95% CI, 10.5 to 13.8)
• Chemotherapy: 6.9 months (95% CI, 5.9 to 7.7)
• HR 0.51 (95% CI, 0.41 to 0.62)

ORR:

• Sacituzumab Govitecan: 83 of 267 (31%)
• Chemotherapy: 11 of 262 (4%)

Safety

Safety Population

The safety population consisted of the 482 patients who received at least one treatment dose: 258 in the sacituzumab govitecan group and 224 in the chemotherapy group.

Safety Summary

Note: Table 3 of the source publication reports treatment-related adverse events only (not all-cause AEs).

Grade 3 and Grade 4 Adverse Events of Clinical Significance

The source publication reported grade 3 and grade 4 events separately. Both grades are presented below.

The most frequent any-grade treatment-related adverse events with sacituzumab govitecan included neutropenia (163 [63%] vs 96 [43%]), diarrhea (153 [59%] vs 27 [12%]), nausea (147 [57%] vs 59 [26%]), alopecia (119 [46%] vs 35 [16%]), and fatigue (115 [45%] vs 68 [30%]).

Concomitant growth-factor support was given to 49% of patients receiving sacituzumab govitecan and 23% of those receiving chemotherapy.

Adverse Events of Special Interest

Rash: Treatment-related rash of any grade occurred in 22 patients (9%) in the sacituzumab govitecan group and 3 patients (1%) in the chemotherapy group. Grade 3 rash occurred in 1 patient in each group.

Ocular toxic effects: Reported in 12 patients (5%) with sacituzumab govitecan and 6 patients (3%) with chemotherapy. No events exceeded grade 1 in either group.

Pneumonitis: Grade 3 pneumonitis developed in 1 patient treated with sacituzumab govitecan.

⚠️ Neutropenia: Critical Safety Signal

• Any grade: 163 (63%) sacituzumab govitecan vs 96 (43%) chemotherapy
• Grade 3: 88 (34%) vs 45 (20%)
• Grade 4: 44 (17%) vs 29 (13%)
• Febrile neutropenia (any grade): 15 (6%) vs 5 (2%)
• Clinical implication: Nearly half of sacituzumab govitecan–treated patients required growth-factor support. Routine complete blood count monitoring is essential. Dose modifications for neutropenia should follow prescribing information guidance.

Deaths

Deaths due to adverse events occurred in 3 patients in each treatment group. In the sacituzumab govitecan group, causes were respiratory failure (2 patients) and postobstructive pneumonia (1 patient) — none were deemed treatment-related. In the chemotherapy group, causes were neutropenic sepsis, sepsis, and general physical health deterioration related to progressive disease (1 each) — the death from neutropenic sepsis was deemed treatment-related.

Subgroup Analyses

Subgroup analyses for the primary endpoint (PFS by BICR, patients without brain metastases) showed a consistent benefit of sacituzumab govitecan across all prespecified subgroups:

These subgroup analyses were prespecified and were not powered for formal statistical comparisons. Results should be interpreted as hypothesis-generating. Notably, the benefit of sacituzumab govitecan was observed regardless of prior checkpoint inhibitor exposure, presence of liver metastases, or number of prior therapy lines.

Key Comparator Trials

Cross-trial comparisons are limited by differences in patient populations, trial designs, and endpoints. These data are presented for context, not for direct statistical comparison.

Contextual Notes

ASCENT is the definitive trial in the later-line metastatic TNBC setting. Before this trial, eribulin was the best-studied option in heavily pretreated breast cancer based on the EMBRACE trial, though EMBRACE enrolled all breast cancer subtypes, not exclusively TNBC [4]. The magnitude of benefit seen with sacituzumab govitecan — a near-doubling of overall survival and more than tripling of PFS — far exceeds what had been achieved by any single agent in this population.

IMpassion130 and KEYNOTE-355 established checkpoint inhibitor–based regimens in the first-line metastatic TNBC setting [5][6], but these trials enrolled treatment-naïve patients, a fundamentally different population from ASCENT. Importantly, ASCENT demonstrated that sacituzumab govitecan was effective even in patients who had previously received PD-1 or PD-L1 inhibitors, addressing a growing clinical need as checkpoint inhibitors move into earlier lines of therapy.

Grey Zones and Unanswered Questions

• Patients with brain metastases were excluded from the primary analysis. Although 61 patients with brain metastases were enrolled and results in the full population (including these patients) were consistent with the primary population, the trial was not designed to evaluate efficacy specifically in patients with active or symptomatic brain metastases. This remains an important gap given the frequency of CNS involvement in metastatic TNBC.

• The optimal sequencing of sacituzumab govitecan relative to checkpoint inhibitors is unknown. ASCENT enrolled patients who had received two or more prior chemotherapy lines. With pembrolizumab now used in the first-line setting for PD-L1–positive TNBC, it is unclear whether prior immunotherapy exposure modifies the benefit from sacituzumab govitecan in ways that subgroup analyses (which showed consistent benefit regardless of prior checkpoint inhibitor use) cannot fully address.

• No head-to-head comparison with other antibody-drug conjugates exists from this trial. Trastuzumab deruxtecan has since demonstrated activity in HER2-low breast cancers, and some patients historically classified as "triple-negative" may harbor HER2-low expression. The relative positioning of sacituzumab govitecan and trastuzumab deruxtecan in the evolving treatment algorithm for patients with low-level HER2 expression remains a critical unanswered question.

• Duration of treatment and benefit beyond progression were not explored. The trial treated patients until disease progression, and no data are provided on subsequent therapy rates or outcomes after sacituzumab govitecan failure. The optimal sequencing of agents after sacituzumab govitecan progression is undefined.

• Approximately 30% of patients had TNBC only at the metastatic confirmation, not at initial diagnosis. While the subgroup analysis suggested consistent benefit regardless of whether TNBC was present at initial diagnosis, the biology and treatment sensitivity of cancers that converted to triple-negative phenotype during treatment may differ from de novo TNBC.

Clinical Implications

Where This Fits in the Treatment Sequence

Sacituzumab govitecan is positioned as a standard treatment option for patients with metastatic triple-negative breast cancer who have received at least two prior systemic therapies in the metastatic setting, including a taxane. In the current (2026) treatment algorithm, first-line therapy for metastatic TNBC typically involves pembrolizumab plus chemotherapy for PD-L1–positive tumors, or chemotherapy alone for PD-L1–negative tumors. PARP inhibitors may be used in patients with germline BRCA mutations. Sacituzumab govitecan then serves as a preferred option in the second line or beyond, per NCCN guidelines [3].

Practical Considerations

Sacituzumab govitecan is administered at 10 mg/kg intravenously on days 1 and 8 of each 21-day cycle. The median relative dose intensity was 99.7%, indicating that most patients received the intended dose without substantial modifications. Dose reductions due to adverse events occurred in 22% of patients. Neutropenia is the dominant toxicity requiring proactive management; growth-factor support was used in 49% of sacituzumab govitecan patients. Complete blood counts should be monitored before each dose. Diarrhea management should include early intervention with antidiarrheal agents. Rash and ocular toxic effects were infrequent and generally low-grade.

Unanswered Questions

The two most practice-relevant open questions are (1) the optimal sequencing of sacituzumab govitecan relative to trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer who also meet TNBC criteria, and (2) whether earlier use of sacituzumab govitecan (e.g., second-line) would produce even greater benefit than demonstrated in this heavily pretreated population.

Post-Progression Options

Subsequent therapy rates after sacituzumab govitecan were not reported in this publication. No crossover to sacituzumab govitecan was permitted in the chemotherapy arm upon progression. Post-progression options in current practice include eribulin, gemcitabine, capecitabine, vinorelbine, or clinical trial enrollment depending on prior exposures and patient fitness.

Regulatory and Guideline Status

Regulatory

• FDA: Sacituzumab govitecan (Trodelvy) received accelerated approval in April 2020 for adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. Regular approval was granted in April 2021 based on the ASCENT trial results. The indication was subsequently expanded to include HR-positive/HER2-negative metastatic breast cancer based on the TROPiCS-02 trial [2].
• EMA: Approved for metastatic TNBC after two or more prior systemic therapies, at least one for metastatic disease.

⚠️ Regulatory status verified as of March 2026. Confirm current approval status and labeled indications before clinical use at FDA.gov.

Guidelines

• NCCN: Sacituzumab govitecan is listed as a preferred regimen for recurrent or metastatic TNBC after prior taxane-containing therapy, with a Category 1 recommendation based on the ASCENT trial [3].

Companion Diagnostics

No companion diagnostic is required. Triple-negative breast cancer status is determined by standard ASCO-CAP testing for ER, PR, and HER2 expression. Trop-2 testing is not required for patient selection.

About the Author

Andrew Stevenson is the founder and systems architect of kill-cancer.com, a clinical intelligence platform delivering structured, source-traced oncology trial analysis to practicing clinicians. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces directly to its source publication. Zero calculation. Zero editorializing. Zero hallucination.

Five siblings lost to cancer built the urgency. The engineering builds the trust.

📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum

Disclaimer

This article is intended for healthcare professionals only. It is not medical advice and should not be used as a substitute for professional clinical judgment. Treatment decisions should be made in consultation with qualified healthcare providers based on individual patient circumstances.

All trial data presented in this article are sourced directly from the published clinical trial report and its supplementary materials. Numbers are reproduced exactly as reported; no calculations, derivations, or estimates have been performed.

Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability.

Comparator trial data presented in Section 8 are sourced from their respective published reports and are provided for contextual purposes only. Cross-trial comparisons have inherent limitations and should not be interpreted as direct statistical comparisons.

References

1. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529-1541. doi:10.1056/NEJMoa2028485
2. Trodelvy (sacituzumab govitecan-hziy) prescribing information. U.S. Food and Drug Administration. Revised 2023.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
4. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914-923.
5. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108-2121.
6. Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817-1828.